👨⚕️ Arzneimittelinformationen zu NuvaRing (Ethinylestradiol und Etonogestrel (Vaginalring)) umfassen Arzneimittelbilder, Nebenwirkungen, Arzneimittelwechselwirkungen, Gebrauchsanweisungen, Symptome einer Überdosierung und was zu vermeiden ist.
NuvaRing für Empfängnisverhütung mit Stimmungsschwankungen, Bauchschmerzen, Unterleibsschmerzen, Schmierblutungen, Libidoverlust Hallo,also ich habe ja von dem Nuvaring eigentlich nur gutes gehört aber der preis ist echt der hammer obwohl ich ja auch immer der meinung war es lohnt sich..so langsam bin ich mir nicht mehr so siche was ich davon halten soll.Reviews: 22
Die NuvaRing kann es zu Bauchschmerzen, vaginale Beschwerden, genitale Juckreiz, verminderte Libido und Gewichtszunahme. Es kann auch dazu führen, einige seltene Nebenwirkungen, die Sehstörungen, Schwindel, einen geschwollenen Bauch, Stimmungsschwankungen oder Schaukeln, Schwierigkeiten oder Schmerzen beim Wasserlassen zählen, Schmerzen oder Blutungen beim Geschlechtsverkehr, …
jemals hatte (siehe Abschnitt 2.2 „Wann ist besondere Vorsicht bei der Anwendung von NuvaRing erforderlich“). Bei Pillen-Anwenderinnen wurde selten über gutartige Lebertumore und noch seltener über bösartige Lebertumore berichtet. Suchen Sie Ihren Arzt auf, wenn unüblich starke Bauchschmerzen …
Apr 29, 2019 · Die hormonelle Empfängnisverhütung mit dem Verhütungsring. Der Nuvaring wirkt aus medizinischer Sicht wie die Pille, macht allerdings keine tägliche Hormoneinnahme nötig. Hier erfahren Sie, wie der Nuvaring wirkt, für wen er sich eignet und wie Sie den Verhütungsring per Online-Rezept bestellen können.Estimated Reading Time: 7 mins
The efficacy and safety of hormonal contraceptive products may be affected with co-administration of anti-HIV protease inhibitors. She should switch from an implant or the IUS on the day of its removal, and from an injectable on the day when the next injection would be due. Unplanned bleeding may vary from slight staining between menstrual periods to breakthrough bleeding, which is a flow much like a regular period. New acceptors of hormonal contraceptive agents should be started on a product containing the lowest hormone content that provides satisfactory results in the individual. It is removed for a one-week break, during which a withdrawal bleed usually occurs. Contraceptive effectiveness may be reduced when hormonal contraceptives are co-administered with some antifungals, anticonvulsants, and other drugs that increase metabolism of contraceptive steroids. Healthcare providers should refer to the label of the individual anti-HIV protease inhibitors for further drug-drug interaction information. Other binding proteins may be elevated in serum. By comparison, the chances of getting pregnant in the first year of typical use not always following directions exactly of other methods of birth control are as follows:. DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. The used ring should be placed in the sachet foil pouch and discarded in a waste receptacle out of the reach of children and pets do not flush in toilet. Vaginal ring placement A vaginal ring is a contraceptive device that contains the hormones estrogen and progestin. The ring is to remain in place continuously for three weeks. NuvaRing has not been studied in postmenopausal women and is not indicated in this population. If the vaginal ring accidentally falls out, rinse the ring with cool or warm — not hot — water and reinsert it within two hours for Annovera or three hours for NuvaRing. Counsel patients regarding the following: Increased risk of cardiovascular events Advise patients that cigarette smoking increases the risk of serious cardiovascular events from use of NuvaRing, and women who are over 35 years old and smoke should not use NuvaRing [see Boxed Warning ]. The attributable risk does provide information about the actual occurrence of a disease in the population. The hydroxylated ethinyl estradiol metabolites have weak estrogenic activity. Tulsa, Oklahoma NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4 mm. Look at the picture of the applicator to familiarize yourself with the parts of the applicator. For further information, the reader is referred to a text on epidemiologic methods. The following serious adverse reactions with the use of CHCs are discussed elsewhere in the labeling. Changing From a CHC: The woman may switch from her previous CHC on any day, but at the latest on the day following the usual hormone-free interval, if she has been using her hormonal method consistently and correctly, or if it is reasonably certain that she is not pregnant. This means that the ring should be removed three weeks later on the same day of the week as it was inserted and at about the same time. Figure 1 shows the risk of developing a VTE for women who are not pregnant and do not use CHCs, for women who use CHCs, for pregnant women, and for women in the postpartum period. Start NuvaRing no earlier than four weeks after a second trimester abortion or miscarriage, due to the increased risk of thromboembolism. Pharmacokinetic data show that the use of tampons has no effect on the systemic absorption of the hormones released by NuvaRing. Ring Breakage: There have been reported cases of NuvaRing disconnecting at the weld joint. Bauchschmerzen , Durchfall. The following chart shows the chance of getting pregnant for women who use different methods of birth control. Carefully monitor prediabetic and diabetic women who are using NuvaRing. Gently push the ring into the barrel. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. In all of these cases, you should use an extra method of birth control, such as a male condom or spermicide, for the first seven days of ring use. How should I start using NuvaRing? Excretion Etonogestrel and ethinyl estradiol are primarily eliminated in urine, bile and feces. Talk to your health care provider about any medications you're taking, including nonprescription and herbal products. If you accidently drop the applicator, wash it with cool to lukewarm water. A new ring is inserted one week after the last ring was removed. It is used to prevent pregnancy. Women on thyroid hormone replacement therapy may need increased doses of thyroid hormone because serum concentrations of thyroid-binding globulin increase with use of CHCs. One of the following two options should be chosen: Insert a new ring immediately. The following additional adverse reactions have been reported in users of combination hormonal contraceptives and are believed to be drug-related:. Ich nutze nun den 3. Remove it for a one-week break and then insert a new ring. They may be signs of a serious problem:. Contraception ; 93— The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks. Deviations from the Recommended Regimen To prevent loss of contraceptive efficacy, women should not deviate from the recommended regimen. Make sure that the ring is not in the applicator. In spite of many studies of the relationship between oral contraceptive use and breast and cervical cancers, a cause-and-effect relationship has not been established. You may need to take a pregnancy test and use a nonhormonal backup method of contraception for one week when you start using a vaginal ring.
If you are a consumer or patient please visit this version. When placed in the vagina, each ring releases on average 0. The molecular weights for etonogestrel and ethinyl estradiol are Combination hormonal contraceptives act by suppression of gonadotropins. Although the primary effect of this action is inhibition of ovulation, other alterations include changes in the cervical mucus which increase the difficulty of sperm entry into the uterus and the endometrium which reduce the likelihood of implantation. Receptor binding studies, as well as studies in animals, have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with low intrinsic androgenicity. The relevance of this latter finding in humans is unknown. Figure 1. Ethinyl estradiol is highly but not specifically bound to serum albumin In vitro data shows that both etonogestrel and ethinyl estradiol are metabolized in liver microsomes by the cytochrome P 3A4 isoenzyme. Ethinyl estradiol is primarily metabolized by aromatic hydroxylation, but a wide variety of hydroxylated and methylated metabolites are formed. These are present as free metabolites and as sulfate and glucuronide conjugates. The hydroxylated ethinyl estradiol metabolites have weak estrogenic activity. The biological activity of etonogestrel metabolites is unknown. Etonogestrel and ethinyl estradiol are primarily eliminated in urine, bile and feces. A single-dose vaginal administration of mg water-based nonoxynol-9 spermicide gel did not affect the serum concentrations of etonogestrel or ethinyl estradiol. The serum concentrations of etonogestrel and ethinyl estradiol were not affected by concomitant administration of oral amoxicillin or doxycycline in standard dosages during 10 days of antibiotic treatment. Table III lists the pregnancy rates for users of various contraceptive methods. Cigarette smoking increases the risk of serious cardiovascular side effects from combination oral contraceptive use. This risk increases with age and with heavy smoking 15 or more cigarettes per day and is quite marked in women over 35 years of age. There is no epidemiologic data available to determine whether safety and efficacy with the vaginal route of administration of combination hormonal contraceptives would be different than the oral route. The use of oral contraceptives is associated with increased risks of several serious conditions including venous and arterial thrombotic and thromboembolic events such as myocardial infarction, thromboembolism, and stroke , hepatic neoplasia, gallbladder disease, and hypertension, although the risk of serious morbidity or mortality is very small in healthy women without underlying risk factors. The risk of morbidity and mortality increases significantly in the presence of other underlying risk factors such as certain inherited thrombophilias, hypertension, hyperlipidemias, obesity, and diabetes. The information contained in this package insert is principally based on studies carried out in women who used oral contraceptives with formulations of higher doses of estrogens and progestogens than those in common use today. The effect of long-term use of oral contraceptives with lower doses of both estrogens and progestogens remains to be determined. Throughout this labeling, epidemiologic studies reported are of two types: retrospective or case control studies and prospective or cohort studies. Case control studies provide a measure of the relative risk of a disease, namely, a ratio of the incidence of a disease among oral contraceptive users to that among non-users. The relative risk does not provide information on the actual clinical occurrence of a disease. Cohort studies provide a measure of attributable risk, which is the difference in the incidence of disease between oral contraceptive users and non-users. The attributable risk does provide information about the actual occurrence of a disease in the population. For further information, the reader is referred to a text on epidemiologic methods. An increased risk of thromboembolic and thrombotic disease associated with the use of oral contraceptives is well established. Case control studies have found the relative risk of users compared to non-users to be three for the first episode of superficial venous thrombosis, four to 11 for deep vein thrombosis or pulmonary embolism, and 1. Cohort studies have shown the relative risk to be somewhat lower, about three for new cases and about 4. The risk of thromboembolic disease associated with oral contraceptives is not related to length of use and disappears after pill use is stopped. In general, these studies indicate an approximate two-fold increased risk, which corresponds to an additional one to two cases of venous thromboembolism per 10, women-years of use. However, data from additional studies have not shown this two-fold increase in risk. A two- to four-fold increase in relative risk of post-operative thromboembolic complications has been reported with the use of oral contraceptives. The relative risk of venous thrombosis in women who have predisposing conditions is twice that of women without such medical conditions. The clinician should be alert to the earliest manifestations of thrombotic disorders thrombophlebitis, pulmonary embolism, cerebrovascular disorders, and retinal thrombosis. An increased risk of myocardial infarction has been attributed to oral contraceptive use. This risk is primarily in smokers or women with other underlying risk factors for coronary artery disease such as hypertension, hypercholesterolemia, morbid obesity, and diabetes. The relative risk of heart attack for current combination oral contraceptive users has been estimated to be two to six. The risk is very low in women under the age of Smoking in combination with oral contraceptive use has been shown to contribute substantially to the incidence of myocardial infarction in women in their mid-thirties or older with smoking accounting for the majority of excess cases. Mortality rates associated with circulatory disease have been shown to increase substantially in smokers, over the age of 35 and non-smokers over the age of 40 among women who use oral contraceptives see Table IV. Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age, and obesity. In particular, some progestogens are known to decrease HDL cholesterol and cause glucose intolerance, while estrogens may create a state of hyperinsulinism. Similar effects on risk factors have been associated with an increased risk of heart disease. Hypertension was found to be a risk factor for both users and non-users, for both types of strokes, while smoking interacted to increase the risk for hemorrhagic strokes. In a large study, the relative risk of thrombotic strokes has been shown to range from three for normotensive users to 14 for users with severe hypertension. The relative risk of hemorrhagic stroke is reported to be 1.
In vitro data shows that both etonogestrel and ethinyl estradiol are metabolized in liver microsomes by the cytochrome P 3A4 isoenzyme. Your health care provider will determine the appropriate timing for you to start using a vaginal ring based on your menstrual cycle and your previous birth control method. Regularly check that NuvaRing is in your vagina for example, before and after intercourse to ensure that you are protected from pregnancy. Advise patients to use a back-up or alternative method of contraception when enzyme inducers are used with NuvaRing [see Drug Interactions 7. Pre-menstrual syndrome Cataracts Cystitis-like syndrome Headache Nervousness Dizziness Hirsutism Loss of scalp hair Erythema multiforme Dysmenorrhea Pancreatitis Erythema nodosum Hemorrhagic eruption Impaired renal function Hemolytic uremic syndrome Acne Changes in libido Colitis Budd-Chiari Syndrome Optic neuritis, which may lead to partial or complete loss of vision. A decline in serum high-density lipoproteins HDL has been reported with many progestational agents. Occasional missed periods may occur with the appropriate use of NuvaRing. If you do not start NuvaRing within 5 days after a first trimester abortion or miscarriage, use a non-hormonal birth control method, such as male condoms and spermicide, while you wait for your period to start. This is a repackaged label. Drug Label Information Updated January 24, If you are a consumer or patient please visit this version. Dispose of throw away the used applicator in the trash can. Etonogestrel : Etonogestrel released by NuvaRing is rapidly absorbed. Small amounts of contraceptive steroids have been identified in the milk of nursing mothers and a few adverse effects on the child have been reported, including jaundice and breast enlargement. Product Information. Choose the position that is most comfortable for you. Women with a history of depression should be carefully observed and the drug discontinued if depression recurs to a serious degree. After no more than a one-week ring-free break, insert a new ring on the same day of the week as it was removed in the last cycle. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. NuvaRing is not included with the applicator. Related Posterior vaginal prolapse rectocele Vaginal atrophy Vaginal ring placement. Table III lists the pregnancy rates for users of various contraceptive methods. Hormonal contraceptives have been shown to cause a decrease in glucose tolerance in some users. Oral contraceptives may compound the effects of well-known risk factors, such as hypertension, diabetes, hyperlipidemias, age, and obesity. A backup method of contraception may not be necessary if you previously used combination birth control pills or the skin patch Xulane , and you insert a vaginal ring on any day up to the day you would have started your new pack of pills or applied a new skin patch. DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Anwendung begonnen und treten nach jedem Einsetzen des Rings ca. Overdosage of combination hormonal contraceptives may cause nausea, vomiting, vaginal bleeding, or other menstrual irregularities. Ich hoffe, dass died so bleiben wird. Inserting a new ring will start the next three-week use period. Your health care provider will review your medical history and check your blood pressure. Contraception ; 93— The following chart shows the chance of getting pregnant for women who use different methods of birth control. Receptor binding studies, as well as studies in animals, have shown that etonogestrel, the biologically active metabolite of desogestrel, combines high progestational activity with low intrinsic androgenicity. The pooled pregnancy rate Pearl Index was 1. These are present as free metabolites and as sulfate and glucuronide conjugates. View Package Photos. Liver Tumors NuvaRing is contraindicated in women with benign and malignant liver tumors [see Contraindications 4 ]. Some studies suggest that combination oral contraceptive use has been associated with an increase in the risk of cervical intraepithelial neoplasia in some populations of women. When placed in the vagina, each ring releases on average 0. If the vaginal ring remains outside of your vagina for longer than two for Annovera or three for NuvaRing hours:. Acute or chronic disturbances of liver function may necessitate the discontinuation of CHC use until markers of liver function return to normal. Some women may experience amenorrhea or oligomenorrhea after discontinuing CHC use, especially when such a condition was pre-existent. Carefully observe women with a history of depression and discontinue NuvaRing use if depression recurs to a serious degree. There are no antidotes and further treatment should be symptomatic. Some progestogens may elevate LDL levels and may render the control of hyperlipidemias more difficult. Overdosage may cause withdrawal bleeding in females and nausea. Die Anwendung an sich fand ich eher unkompliziert.
If you are a consumer or patient please visit this version. One NuvaRing is inserted in the vagina. The ring must remain in place continuously for three weeks, followed by a one-week ring-free interval. NuvaRing is a polymeric vaginal ring containing Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of CHCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with CHCs. Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive CHC use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. To achieve maximum contraceptive effectiveness, NuvaRing must be used as directed [see Dosage and Administration 2. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed. The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina. The exact position of NuvaRing inside the vagina is not critical for its function. The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks. This means that the ring should be removed three weeks later on the same day of the week as it was inserted and at about the same time. NuvaRing can be removed by hooking the index finger under the forward rim or by grasping the rim between the index and middle finger and pulling it out. The used ring should be placed in the sachet foil pouch and discarded in a waste receptacle out of the reach of children and pets do not flush in toilet. After a one-week break, during which a withdrawal bleed usually occurs, a new ring is inserted on the same day of the week as it was inserted in the previous cycle. The withdrawal bleed usually starts on Day after removal of the ring and may not have finished before the next ring is inserted. In order to maintain contraceptive effectiveness, the new ring must be inserted exactly one week after the previous one was removed even if menstrual bleeding has not finished. The woman should insert NuvaRing on the first day of her menstrual bleeding. NuvaRing may also be started on Days of the woman's cycle, but in this case a barrier method, such as male condoms with spermicide, should be used for the first seven days of NuvaRing use in the first cycle. The woman may switch from her previous CHC on any day, but at the latest on the day following the usual hormone-free interval, if she has been using her hormonal method consistently and correctly, or if it is reasonably certain that she is not pregnant. She should switch from an implant or the IUS on the day of its removal, and from an injectable on the day when the next injection would be due. In all of these cases, the woman should use an additional barrier method such as a male condom with spermicide, for the first seven days. The woman may start using NuvaRing within the first five days following a complete first trimester abortion or miscarriage, and she does not need to use an additional method of contraception. If use of NuvaRing is not started within five days following a first trimester abortion or miscarriage, the woman should follow the instructions for "No Hormonal Contraceptive Use in the Preceding Cycle. Start NuvaRing no earlier than four weeks after a second trimester abortion or miscarriage, due to the increased risk of thromboembolism. The use of NuvaRing may be initiated no sooner than four weeks postpartum in women who elect not to breastfeed, due to the increased risk of thromboembolism in the postpartum period. Advise women who are breastfeeding not to use NuvaRing but to use other forms of contraception until the child is weaned. If a woman begins using NuvaRing postpartum, instruct her to use an additional method of contraception, such as male condoms with spermicide, for the first seven days. If she has not yet had a period, consider the possibility of ovulation and conception occurring prior to initiation of NuvaRing. To prevent loss of contraceptive efficacy, advise women not to deviate from the recommended regimen. NuvaRing should be left in the vagina for a continuous period of three weeks. Advise women to regularly check for the presence of NuvaRing in the vagina for example, before and after intercourse. NuvaRing can be accidentally expelled, for example, while removing a tampon, during intercourse, or with straining during a bowel movement. If the ring is accidentally expelled and is left outside of the vagina for less than three hours , contraceptive efficacy is not reduced. NuvaRing can be rinsed with cool to lukewarm not hot water and reinserted as soon as possible, but at the latest within three hours. If NuvaRing is lost, a new vaginal ring should be inserted and the regimen should be continued without alteration. During Weeks 1 and 2: Contraceptive efficacy may be reduced. The woman should reinsert the ring as soon as she remembers. A barrier method such as male condoms with spermicides must be used until the ring has been used continuously for seven days. During Week 3: The woman should discard that ring. One of the following two options should be chosen:. In either case, a barrier method such as male condoms with spermicides must be used until the new ring has been used continuously for seven days.